Nivolumab (PD-1 inhibitor)
Treatment for Hodgkin Lymphoma
Typical Dosage: 240 mg IV every 2 weeks or 480 mg IV every 4 weeks
Effectiveness
70%
Safety Score
45%
Clinical Trials
14
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
240 mg IV every 2 weeks or 480 mg IV every 4 weeks
Time to Effect
Weeks to months
Treatment Duration
Until progression or unacceptable toxicity (can be years)
Evidence Quality
HIGHConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$160,000
Monitoring:$7,500
Side Effect Mgmt:$5,000
Total Annual:$172,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$500,000/QALY
QALYs Gained
2
Outcome-Based Costs
Cost per Responder
$265,385
Cost per Remission
$690,000
Nivolumab (PD-1 inhibitor) Outcomes
for Hodgkin Lymphoma
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+65%
Remission Rate
+25%
Common Side Effects
Fatigue
+35%
Rash
+25%
Diarrhea
+20%
Pruritus
+25%
Hypothyroidism (Immune-related)
+15%
Pneumonitis (Immune-related)
+4%
Active Clinical Trials
9 active trials recruiting for Nivolumab (PD-1 inhibitor) in Hodgkin Lymphoma
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
NCT04134325ACTIVE NOT RECRUITINGEARLY_PHASE1
10 participants
INTERVENTIONAL
Chapel Hill, United States
Started: Sep 1, 2019
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
NCT06812858RECRUITINGPHASE2
83 participants
INTERVENTIONAL
Astana, Kazakhstan +2 more
Started: Sep 2, 2024
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
NCT03843294ACTIVE NOT RECRUITINGPHASE1
18 participants
INTERVENTIONAL
Salt Lake City, United States
Started: Jun 24, 2019
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
NCT06767956NOT YET RECRUITINGPHASE1, PHASE2
30 participants
INTERVENTIONAL
Pittsburgh, United States
Started: Jun 30, 2025
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
NCT03884998ACTIVE NOT RECRUITINGPHASE1
27 participants
INTERVENTIONAL
Duarte, United States +2 more
Started: Feb 26, 2019
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
NCT05352828ACTIVE NOT RECRUITINGPHASE1
15 participants
INTERVENTIONAL
Duarte, United States +4 more
Started: Jul 25, 2022
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
NCT02879695ACTIVE NOT RECRUITINGPHASE1
28 participants
INTERVENTIONAL
New Haven, United States +6 more
Started: Oct 25, 2017
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399RECRUITINGPHASE2
461 participants
INTERVENTIONAL
Birmingham, United States +214 more
Started: Dec 17, 2020
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
NCT03017820RECRUITINGPHASE1
127 participants
INTERVENTIONAL
Scottsdale, United States +1 more
Started: Apr 4, 2017
Completed Clinical Trials
3 completed trials for Nivolumab (PD-1 inhibitor) in Hodgkin Lymphoma
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
NCT02973113COMPLETEDPHASE1
8 participants
INTERVENTIONAL
Houston, United States +1 more
Started: Feb 16, 2016
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
NCT03229278COMPLETEDPHASE1
14 participants
INTERVENTIONAL
New Brunswick, United States
Started: Oct 3, 2017
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
NCT03190174COMPLETEDPHASE1, PHASE2
34 participants
INTERVENTIONAL
Santa Monica, United States
Started: Aug 24, 2017